Rezidivierende Harnwegsinfektionen – was tun?

Was ist neu?

Nicht antibiotische Therapieregime Neben allgemeiner Aufklärung und Beratung über Risikofaktoren von Harnwegsinfektionen sind vor allem die nichtantibiotischen Therapie-Optionen zur Rezidivreduktion wichtig. Das Ziel hierbei ist es, Resistenzentwicklungen und den entsprechenden unerwünschten Nebenwirkungen von Antibiotika vorzubeugen. Zu den nicht antibiotischen Strategien zählen allen voran eine persönliche Beratung mit Vermittlung von Verhaltensempfehlungen, die Immunoprophylaxe, Phytotherapeutika, sowie eine lokale Östrogensubstitution

Antibiotische Prävention Bei hohem Leidensdruck der Patientinnen ist jedoch nach entsprechender Abwägung auch eine antibiotische Prophylaxe in Betracht zu ziehen. Zusammenfassend sollte eine individuelle Beratung erfolgen und es sollte mit einem multimodalen Therapieansatz behandelt werden.

Abstract

Urinary tract infections are among the most common bacterial infections. A significant proportion of urinary tract infections recur, which leads to impairments in patientsʼ physical intimacy, social contacts and ability to work. The standardised ACSS questionnaire can provide help in establishing a diagnosis and assessing the course of the disease. In addition to general education and counselling on risk factors for urinary tract infections, non-antibiotic treatment options are particularly important for reducing recurrence. This aims to prevent the development of resistance to antibiotics and their undesirable side-effects. Non-antibiotic strategies most notably include personal counselling with communication of behavioural recommendations, immunoprophylaxis, phytotherapeutics and local oestrogen substitution. However, in cases of high patient suffering, antibiotic prophylaxis should also be considered after due deliberation. In summary, individual counselling should take place and treatment should be given in a multimodal therapeutic approach.

Schlüsselwörter

Harnwegsinfektion - Prävention - rHWI - nichtantibiotische Therapieoptionen - Zystitis

Key words

rUTI - urinary tract infection - cystitis - prevention - non-antibiotic treatment options

Publication History

Article published online:
28 August 2022

• Literatur

• 1 Wagenlehner F, Schmiemann G. Leitlinienprogramm DGU: Interdisziplinäre S3 Leitlinie: Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. Langversion 1.1-2, 2017 AWMF Registernummer: 043/044. (Zugriff am: 18.12.20). http://www.awmf.org
• 2 Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med 2003; 349: 259-266 DOI: 10.1056/NEJMcp030027.
• 3 McLaughlin SP, Carson CC. Urinary tract infections in women. Med Clin North Am 2004; 88: 417-429 DOI: 10.1016/S0025-7125(03) 00148-2.
• 4 Giesen LG, Cousins G, Dimitrov BD. et al. Predicting acute uncomplicated urinary tract infection in women: a systematic review of the diagnostic accuracy of symptoms and signs. BMC Fam Pract 2010; 11: 78 DOI: 10.1186/1471-2296-11-78.
• 5 Alidjanov JF, Abdufattaev UA, Makhsudov SA. et al. New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol Int 2014; 92: 230-236 DOI: 10.1159/000356177.
• 6 Alidjanov JF, Pilatz A, Abdufattaev UA. et al. German validation of the Acute Cystitis Symptom Score. Urologe A 2015; 54: 1269-1276 DOI: 10.1007/s00120-015-3873-5.
• 7 Funfstuck R, Stein G, Naber KG. et al. Nephrology-part 3: Urinary tract infections. Med Klin (Munich) 2003; 98: 377-387 DOI: 10.1007/s00063-003-1275-8.
• 8 Graham JC, Galloway A. ACP Best Practice No 167: the laboratory diagnosis of urinary tract infection. J Clin Pathol 2001; 54: 911-919 DOI: 10.1136/jcp.54.12.911.
• 9 Bonkat G, Bartoletti RR, Bruyère F. et al. EAU Guidelines on Urological Infections. presented at the EAU Annual Congress. Amsterdam the Netherlands: EAU Annual Congress; 2020. ISBN: 978-94-92671-07-3
• 10 Foxman B, Frerichs RR. Epidemiology of urinary tract infection: I. Diaphragm use and sexual intercourse. Am J Public Health 1985; 75: 1308-1313 DOI: 10.2105/ajph.75.11.1308.
• 11 Hooton TM, Scholes D, Hughes JP. et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996; 335: 468-474 DOI: 10.1056/NEJM199608153350703.
• 12 Hooton TM, Scholes D, Stapleton AE. et al. A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med 2000; 343: 992-997 DOI: 10.1056/NEJM200010053431402.
• 13 Scholes D, Hooton TM, Roberts PL. et al. Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000; 182: 1177-1182 DOI: 10.1086/315827.
• 14 Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329: 753-756 DOI: 10.1056/NEJM199309093291102.
• 15 de With K, Kern W. Leitlinienprogramm DGI: Interdisziplinäre S3 Leitlinie: Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. Langversion, AWMF Registernummer 092/001 – update 2018. (Zugriff am 21.12.20). https://www.awmf.org
• 16 Lumsden L, Hyner GC. Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients. Women Health 1985; 10: 79-86 DOI: 10.1300/J013v10n01_06.
• 17 Vahlensieck W, Bauer HW, Piechota HJ. et al. Prophylaxis of recurrent urinary tract infections. Urologe A 2014; 53: 1468-1475 DOI: 10.1007/s00120-014-3562-9.
• 18 Hooton TM, Vecchio M, Iroz A. et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med 2018; 178: 1509-1515 DOI: 10.1001/jamainternmed.2018.4204.
• 19 Kontiokari T, Laitinen J, Jarvi L. et al. Dietary factors protecting women from urinary tract infection. Am J Clin Nutr 2003; 77: 600-604 DOI: 10.1093/ajcn/77.3.600.
• 20 Semins MJ, Shore AD, Makary MA. et al. The impact of obesity on urinary tract infection risk. Urology 2012; 79: 266-269 DOI: 10.1016/j.urology.2011.09.040.
• 21 Wagenlehner FM, Vahlensieck W, Bauer HW. et al Primary and secondary prevention of urinary tract infections. Urologe A 2011; 50 : 1248–1250-1242, 1254-1246. DOI: 10.1007/s00120-011-2616-5.
• 22 Vahlensieck W, Bauer H-W. Vorbeugende Therapie chronisch rezidivierender Harnwegsinfektionen (rHWI). Med Welt 2012; 63: 185-190
• 23 Vahlensieck W, Bauer H-W, Hoyme UB. et al. Prophylaxe rezidivierender Harnwegsinfektionen (rHWI). Nieren- und Hochdruckkrankheiten 2007; 36: 501-513 DOI: 10.5414/NHP36501.
• 24 Amiri FN, Rooshan MH, Ahmady MH. et al. Hygiene practices and sexual activity associated with urinary tract infection in pregnant women. East Mediterr Health J 2009; 15: 104-110
• 25 Baerheim A, Laerum E. Symptomatic lower urinary tract infection induced by cooling of the feet. A controlled experimental trial. Scand J Prim Health Care 1992; 10: 157-160 DOI: 10.3109/02813439209014054.
• 26 Minardi D, dʼAnzeo G, Cantoro D. et al. Urinary tract infections in women: etiology and treatment options. Int J Gen Med 2011; 4: 333-343 DOI: 10.2147/IJGM.S11767.
• 27 De Paepe H, Hoebeke P, Renson C. et al. Pelvic-floor therapy in girls with recurrent urinary tract infections and dysfunctional voiding. Br J Urol 1998; 81 (Suppl. 03) 109-113 DOI: 10.1046/j.1464-410x.1998.00021.x.
• 28 Bauer HW, Rahlfs VW, Lauener PA. et al. Prevention of recurrent urinary tract infections with immuno-active E.coli fractions: a metaanalysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents 2002; 19: 451-456 DOI: 10.1016/s0924-8579(02)00106-1.
• 29 Naber KG, Cho YH, Matsumoto T. et al. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents 2009; 33: 111-119 DOI: 10.1016/j.ijantimicag.2008.08.011.
• 30 Beerepoot MA, Geerlings SE, van Haarst EP. et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol 2013; 190: 1981-1989 DOI: 10.1016/j.juro.2013.04.142.
• 31 Vahlensieck W. Prophylaxemaßnahmen bei rezidivierenden Harnwegsinfektionen. In: Hofstetter A. Urogenitale Infektionen. Berlin, Heidelberg: Springer; 1999: 215-239
• 32 Aune A, Alraek T, LiHua H. et al. Acupuncture in the prophylaxis of recurrent lower urinary tract infection in adult women. Scand J Prim Health Care 1998; 16: 37-39 DOI: 10.1080/028134398750003386.
• 33 Alraek T, Soedal LI, Fagerheim SU. et al. Acupuncture treatment in the prevention of uncomplicated recurrent lower urinary tract infections in adult women. Am J Public Health 2002; 92: 1609-1611 DOI: 10.2105/ajph.92.10.1609.
• 34 Kranjcec B, Papes D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol 2014; 32: 79-84 DOI: 10.1007/s00345-013-1091-6.
• 35 Notelovitz M. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. Maturitas 1995; 22: S31-S33 DOI: 10.1016/0378-5122(95)00960-4.
• 36 Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103-111 DOI: 10.1007/s10549-007-9523-x.
• 37 Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006; 108: 1354-1360 DOI: 10.1097/01.AOG.0000241091.86268.6e.
• 38 Nicolle LE. Prophylaxis: recurrent urinary tract infection in women. Infection 1992; 20 (Suppl. 03) S203-S205 discussion S206-S210 DOI: 10.1007/BF01704376.
• 39 Flower A, Bishop FL, Lewith G. How women manage recurrent urinary tract infections: an analysis of postings on a popular web forum. BMC Fam Pract 2014; 15: 162 DOI: 10.1186/1471-2296-15-162.